Theresa Tse

Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong.

Beijing Tide Pharmaceutical Co., Ltd. engages in research, development, manufacturing and sale of pharmaceutical products. The firm's products include kaifen flurbiprofen axetil injection, kaishi alprostadil injection, kaina beraprost sodium tablet and deyou pronase granules. The company was founded in May 1995 and is headquartered in Beijing, China.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu.